Financial Data Highlights: Ovid Therapeutics Inc. (NASDAQ: OVID) reported in its latest financial statement that as of December 31, 2025, the company held a total of $90.4 million in cash, cash equivalents, and marketable securities.

Financial Data Highlights: Ovid Therapeutics Inc. (NASDAQ: OVID) reported in its latest financial statement that as of December 31, 2025, the company held a total of $90.4 million in cash, cash equivalents, and marketable securities.

老虎证券2026/03/18 10:23

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This data provides clear financial support for the subsequent development of innovative drugs for neurological diseases. **Industry Background and Capital Efficiency** The current financing environment in the biotechnology industry is showing a trend of polarization. Against the backdrop of the Federal Reserve maintaining high interest rates, the IPO window for unprofitable biotech companies continues to narrow, highlighting the value of cash reserves for existing listed companies. Ovid Therapeutics focuses on the field of rare neurological diseases, with its main pipeline including Angelman syndrome therapy OV101 and epilepsy drug OV935. Its cash reserves are sufficient to support at least 24 months of core clinical advancement. Compared to its peers, several small and medium-sized biotech companies have recently cut R&D spending due to funding chain issues, while Ovid’s cash position provides support for gaining a differentiated advantage in the competition for neurological disease targets. **R&D Progress and Capital Allocation** The company's recently disclosed R&D roadmap shows that $90.4 million in funds will be prioritized for advancing the collection of phase III clinical follow-up data for OV101, as well as combination drug trials of OV935 with pharmaceutical giants. Notably, its cash burn rate has remained at around $11 million per quarter over the past four quarters. If the current operational efficiency is maintained, existing funds can cover key clinical milestones through 2027. **Market Response and Valuation Reference** After the financial report was released, Ovid’s stock price fluctuated by less than 1% in after-hours trading, reflecting that the market had fully priced in expectations for its cash position. Wall Street analysts generally believe that the core driver of the company’s valuation still depends on the clinical data readout in 2026, rather than short-term financial indicators. JPMorgan pointed out in its latest report that Ovid’s cash safety margin can reduce investors’ concerns about financing dilution risk, but attention should be paid to whether a new round of financing will be needed in the second half of 2026. **Competitive Landscape in the Neurological Disease Track** In the Angelman syndrome field, Ovid’s main competitor, Neurocrine Biosciences, has already obtained approval for INGREZZA in certain subtypes, while if OV101 achieves positive data in 2026, it is expected to become the first targeted treatment option for this disease. The current global Angelman syndrome drug market is estimated to reach $2 billion, but the regulatory threshold is high, and cash reserves will directly determine whether companies can persist until the approval stage.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

October 9 - ** Shares of Australian Maas Group (MGH.AX) have fallen more than 27% so far this week and are set for their worst weekly performance if the downward trend continues. ** On Thursday, media reported that Firmus, backed by Nvidia, might reduce the size of its AUD 5 billion Australian IPO (link), sparking investor concerns and leading to a 30% plunge in shares of construction services provider MGH. ** MGH holds a 3.2% stake in this AI data center operator. ** MGH suspended trading on Friday (link), pending an announcement related to Firmus. Firmus has shelved its AUD 5 billion listing plan due to market volatility and conditions. ** Before the suspension, MGH's shares had already fallen over 8% this year. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. This automated translation may contain inaccuracies or omit the desired context; Reuters does not guarantee the accuracy of automated translations and provides them solely for reader convenience. Reuters accepts no liability for any harm or loss caused by the use of automated translations.)

路透社•2026/10/09 01:26

Apple to launch dual products in October: First touch-screen MacBook and new iPad mini to debut simultaneously

Apple is planning to hold its second product launch event of the month around October 27, where it will introduce its first-ever touchscreen MacBook Pro (featuring an OLED display and the “Dynamic Island” interface), a new iPad mini (also upgraded with OLED and a repositioned camera), as well as a 14-inch MacBook Pro and iMac powered by the M6 chip. These are the first major products overseen by the new CEO, John Ternus.

华尔街见闻•2026/10/09 01:01

BUZZ - Driven by active trading, the Australian Securities Exchange (ASX) is on track for its best week in two months

October 9 – The stock price of ASX ASX.AX, the operator of the Australian Securities Exchange, has risen more than 3.8% so far this week, on track for its best weekly performance since early August. On Thursday, Citi raised its annual earnings per share (EPS) forecast for ASX by 2%, citing continued strong trading activity. On Friday, the stock was up as much as 0.3% to 60.79 AUD. Citi also holds a positive view of ASX’s new CEO, Anthony Attia, agreeing with his approach of bringing in external talent and modernizing technology. Including the latest gain, the stock is up 18% year-to-date. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. Since automated translations may contain errors or lack context, Reuters does not guarantee the accuracy of the translation. The automated translation is provided solely for the convenience of readers, and Reuters accepts no liability for any damage or loss arising from the use of the automated translation.)

路透社•2026/10/09 00:56

Goldman Sachs upgrades Palantir (PLTR.US) to "Buy" with a price target of $230, optimistic about AI growth continuing through 2027.

Goldman Sachs has upgraded enterprise software company Palantir from "Neutral" to "Buy," citing the company's recent underperformance in stock price and increased valuation attractiveness.

智通财经•2026/10/09 00:46